Industry News (Clinical Trials)

IND Filed for MiKasome To Treat Infections

Published in TB and Outbreaks Week, October 21st, 1996

NeXstar Pharmaceuticals, Inc., Boulder, Colorado, announced that it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for clinical testing of MiKasome in patients with a variety of serious bacterial and mycobacterial infections.

MiKasome is a proprietary liposomal antibiotic designed to improve the efficacy and decrease the toxicity associated with a family of antibiotics known as aminoglycosides. Amikacin, the active ingredient in MiKasome, is a member of the aminoglycoside family.

The initial U.S. clinical trial for MiKasome involves up to 30 asymptomatic HIV infected men and women over 18...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-10-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry